Kelly Bethel

Kelly Bethel

Auto-generated profile, based on publicly available information

Kelly Bethel

Scripps Clinic Medical Group/Scripps Health, La Jolla, CA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Physical Biology
Verified
Journal Article
Closed access
DMDena Marrinucci
Dena Marrinucci
KBKelly Bethel
Kelly Bethel
AKAnand Kolatkar
Anand Kolatkar
MLMadelyn S Luttgen
Madelyn S Luttgen
MMMichael Malchiodi
Michael Malchiodi
PKPeter Kuhn
Peter Kuhn
Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are unknown. We have established a fluid phase biopsy approach that identifies circulating tumor cells (CTCs) without using surface protein-based enrichment and presents them in sufficiently high definition (HD) to satisfy diagnostic pathology image quality requirements. This 'HD-CTC' assay finds >5 HD-CTCs mL(-1) of blood in 80% of patients with metastatic prostate cancer (n = 20), in 70% of patients with metastatic breast cancer (n = 30), in 50% of patients with metastatic pancreatic cancer (n = 18), and in 0% of normal controls (n = 15). Additionally, it finds HD-CTC clusters ranging from 2 HD-CTCs to greater than 30 HD-CTCs in the majority of these cancer patients. This initial validation of an enrichment-free assay demonstrates our ability to identify significant numbers of HD-CTCs in a majority of patients with prostate, breast and pancreatic cancers.

1 February 2012 in Physical Biology
Verified
Journal Article
Closed access
ECEdward H Cho
Edward H Cho
MWMarco Wendel
Marco Wendel
MLMadelyn Luttgen
Madelyn Luttgen
CYCraig Yoshioka
Craig Yoshioka
DMDena Marrinucci
Dena Marrinucci
PKPeter Kuhn
Peter Kuhn
Circulating tumor cells (CTCs) have been implicated as a population of cells that may seed metastasis and venous thromboembolism (VTE), two major causes of mortality in cancer patients. Thus far, existing CTC detection technologies have been unable to reproducibly detect CTC aggregates in order to address what contribution CTC aggregates may make to metastasis or VTE. We report here an enrichment-free immunofluorescence detection method that can reproducibly detect and enumerate homotypic CTC aggregates in patient samples. We identified CTC aggregates in 43% of 86 patient samples. The fraction of CTC aggregation was investigated in blood draws from 24 breast, 14 non-small cell lung, 18 pancreatic, 15 prostate stage IV cancer patients and 15 normal blood donors. Both single CTCs and CTC aggregates were measured to determine whether differences exist in the physical characteristics of these two populations. Cells contained in CTC aggregates had less area and length, on average, than single CTCs. Nuclear to cytoplasmic ratios between single CTCs and CTC aggregates were similar. This detection method may assist future studies in determining which population of cells is more physically likely to contribute to metastasis and VTE.

26 April 2013 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TNThe Physical Sciences - Oncology Centers Network
The Physical Sciences - Oncology Centers Network
DADavid B. Agus
David B. Agus
JAJenolyn F. Alexander
Jenolyn F. Alexander
WAWadih Arap
Wadih Arap
Shashaanka AshiliShashaanka Ashili
Shashaanka Ashili
PWPei-Hsun Wu
Pei-Hsun Wu
To investigate the transition from non-cancerous to metastatic from a physical sciences perspective, the Physical Sciences–Oncology Centers (PS-OC) Network performed molecular and biophysical comparative studies of the non-tumorigenic MCF-10A and metastatic MDA-MB-231 breast epithelial cell lines, commonly used as models of cancer metastasis. Experiments were performed in 20 laboratories from 12 PS-OCs. Each laboratory was supplied with identical aliquots and common reagents and culture protocols. Analyses of these measurements revealed dramatic differences in their mechanics, migration, adhesion, oxygen response, and proteomic profiles. Model-based multi-omics approaches identified key differences between these cells' regulatory networks involved in morphology and survival. These results provide a multifaceted description of cellular parameters of two widely used cell lines and demonstrate the value of the PS-OC Network approach for integration of diverse experimental observations to elucidate the phenotypes associated with cancer metastasis.

1 April 2006 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
HHH. Ben Hsieh
H. Ben Hsieh
DMDena Marrinucci
Dena Marrinucci
KBKelly Bethel
Kelly Bethel
DCDouglas N. Curry
Douglas N. Curry
MHMark Humphrey
Mark Humphrey
JNJorge Nieva
Jorge Nieva

1 November 2014 in Clinical Immunology
Verified
Journal Article
Closed access
HWHannah H. Walford
Hannah H. Walford
SLSean J. Lund
Sean J. Lund
RBRachel E. Baum
Rachel E. Baum
AWAndrew A. White
Andrew A. White
CBChristopher M. Bergeron
Christopher M. Bergeron
TDTaylor A Doherty
Taylor A Doherty

1 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAngel E. Dago
Angel E. Dago
ASAsya Stepansky
Asya Stepansky
ACAnders Carlsson
Anders Carlsson
MLMadelyn Luttgen
Madelyn Luttgen
JKJude Kendall
Jude Kendall
Peter KuhnPeter Kuhn
Peter Kuhn
Timely characterization of a cancer's evolution is required to predict treatment efficacy and to detect resistance early. High content analysis of single Circulating Tumor Cells (CTCs) enables sequential characterization of genotypic, morphometric and protein expression alterations in real time over the course of cancer treatment. This concept was investigated in a patient with castrate-resistant prostate cancer progressing through both chemotherapy and targeted therapy. In this case study, we integrate across four timepoints 41 genome-wide copy number variation (CNV) profiles plus morphometric parameters and androgen receptor (AR) protein levels. Remarkably, little change was observed in response to standard chemotherapy, evidenced by the fact that a unique clone (A), exhibiting highly rearranged CNV profiles and AR+ phenotype was found circulating before and after treatment. However, clinical response and subsequent progression after targeted therapy was associated with the drastic depletion of clone A, followed by the sequential emergence of two distinct CTC sub-populations that differed in both AR genotype and expression phenotype. While AR- cells with flat or pseudo-diploid CNV profiles (clone B) were identified at the time of response, a new tumor lineage of AR+ cells (clone C) with CNV altered profiles was detected during relapse. We showed that clone C, despite phylogenetically related to clone A, possessed a unique set of somatic CNV alterations, including MYC amplification, an event linked to hormone escape. Interesting, we showed that both clones acquired AR gene amplification by deploying different evolutionary paths. Overall, these data demonstrate the timeframe of tumor evolution in response to therapy and provide a framework for the multi-scale analysis of fluid biopsies to quantify and monitor disease evolution in individual patients.